Abstracts

396 – SIV-Producing Macrophages From the CNS Seed Deep Cervical Lymph Nodes After ART Interruption

Background The cell types that contribute to viral rebound after antiretroviral therapy interruption (ATI) in people living with HIV or experimental SIV-infected macaques are not well understood. Further, the mechanisms and impact of central nervous system (CNS) reservoirs in viral recrudescence after ATI remain unclear. Deep cervical lymph nodes (dCLN) drain the CNS, and productively…

460 – CSF and Plasma JCV-DNA Changes as Prognostic Marker in Progressive Multifocal Leukoencephalopathy

Background Background. Progressive Multifocal Leukoencephalopathy (PML) is a severe demyelinating disease caused by JC virus (JCV) reactivation. CSF JCV-DNA level at diagnosis and its variation over time may help predict outcome. The aim was to study plasma JCV-DNA level changes, in addition to CSF, to assess its prognostic potential. Methods Methods. We selected cases from…

503 – Efficacy and Safety of Switching to DTG/3TC Dual Therapy From B/F/TAF Among Older Adults ≥60 Years 

Background Use of two drug antiretroviral regimens such as dolutegravir/lamivudine (DTG/3TC) minimises exposure to NRTIs reducing drug toxicities that overlap with co-morbidities common in older persons living with HIV. The efficacy of dolutegravir/lamivude has been demonstrated in persons with no history of prior virological failure. We evaluated the efficacy and safety of switching older adults…

514 – Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: 96-Week Update From a Blinded Phase III Study

Background The NNRTI doravirine (DOR) and the investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) islatravir (ISL) have complementary mechanisms of action and resistance profiles. The primary analysis of the MK8591A-052 study in people living with HIV-1 demonstrated that switching to DOR/ISL 100 mg/0.25 mg was noninferior to continuing bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in maintaining virologic suppression…

535 – Dolutegravir/Lamivudine in People With HIV With and Without Prior Virologic Failure in Thailand

Background Dolutegravir plus lamivudine (DTG+3TC) is recommended for ART-naïve and virologicallysuppressed people with HIV (PWH). Evidence on its effectiveness in treatment-experiencedindividuals with prior virological failure or resistance, particularly in low- and middle-incomecountries (LMICs), remains limited. We assessed real-world outcomes of DTG+3TC inThailand’s National AIDS Program (NAP). Methods We conducted a retrospective cohort study using de-identified…

540 – Real-World Use of Lenacapavir in France: A National, Observational Study

Background French guidelines recommend lenacapavir (LEN) for people with HIV (PWH) with multidrug-resistant virus who cannot achieve viral suppression with oral antiretroviral therapy (ART), pending validation by a multidisciplinary committee. The LENAddOn national study aims to: characterize PWH initiating LEN post-early access program in France; assess LEN continuation rates at month (M)6 and M12; describe…

827 – Maternal and Infant Predictors of Mortality in Liveborn Infants in the IMPAACT 2010 (VESTED) Trial

Background The IMPAACT 2010 (VESTED) randomized trial compared dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide fumarate (FTC/TAF); DTG plus FTC/tenofovir disoproxil fumarate (TDF) and efavirenz (EFV)/FTC/TDF initiated during pregnancy among 643 women in 9 countries (predominantly in Africa). Previous analyses showed superior virologic efficacy and pregnancy outcomes with DTG-based compared with EFV-based ART. We conducted an exploratory…

568 – Virologic Failure to CAB+RPV LAI in Real Life: Resistance and Outcomes in a Large Italian Cohort

Background Although virological failure (VF) with Long-acting injectable (LAI) regimen with cabotegravir (CAB) and rilpivirine (RPV) is rare, it is frequently accompanied by integrase inhibitor (INI) and NNRTI resistance, potentially compromising future ART options. We aimed to characterize real-life CAB+RPV LAI failures, resistance and post-failure outcomes in Italy.  Methods We conducted a retrospective observational cohort study including…

877 – European HIV-1 A6 International Transmission Networks Are Enriched by Migrating Populations

Background HIV-1 sub-subtype A6 propels the growing HIV epidemic in Eastern Europe. Long-lasting migration, including war-related displacement from Ukraine, has introduced this lineage into multiple European countries resulting in expanding transmission dynamics in the region. Here we aimed to provide insight on the international A6 transmission patters across selected European regions including enrichment related to…